BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35278032)

  • 1. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
    Sawamoto R; Oba K; Matsuyama Y
    Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data.
    Liu M; Bunn V; Hupf B; Lin J; Lin J
    Stat Med; 2021 Sep; 40(22):4794-4808. PubMed ID: 34126656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive design for covariate-adaptive historical control information borrowing.
    Jin H; Kim MO; Scheffler A; Jiang F
    Stat Med; 2023 Dec; 42(29):5338-5352. PubMed ID: 37750361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
    Wang X; Suttner L; Jemielita T; Li X
    J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical appraisal of Bayesian dynamic borrowing from an imperfectly commensurate historical control.
    Harun N; Liu C; Kim MO
    Pharm Stat; 2020 Sep; 19(5):613-625. PubMed ID: 32185886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.
    Harun N; Gupta N; McCormack FX; Macaluso M
    Clin Trials; 2023 Jun; 20(3):223-234. PubMed ID: 36927115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian selective response-adaptive design using the historical control.
    Kim MO; Harun N; Liu C; Khoury JC; Broderick JP
    Stat Med; 2018 Nov; 37(26):3709-3722. PubMed ID: 29900577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
    Hupf B; Bunn V; Lin J; Dong C
    Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints.
    Bi D; Liu M; Lin J; Liu R
    Stat Med; 2023 Dec; 42(30):5708-5722. PubMed ID: 37858287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel equivalence probability weighted power prior for using historical control data in an adaptive clinical trial design: A comparison to standard methods.
    Bennett M; White S; Best N; Mander A
    Pharm Stat; 2021 May; 20(3):462-484. PubMed ID: 33474798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel power prior approach for borrowing historical control data in clinical trials.
    Shi Y; Li W; Liu GF
    Stat Methods Med Res; 2023 Mar; 32(3):493-508. PubMed ID: 36601652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data.
    Zhang W; Pan Z; Yuan Y
    J Biopharm Stat; 2022 May; 32(3):359-372. PubMed ID: 35679137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging external evidence using Bayesian hierarchical model and propensity score in the presence of covariates.
    Chen X; Yao Y; Wang L; Mukhopadhyay S
    Contemp Clin Trials; 2023 Sep; 132():107301. PubMed ID: 37467950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating historical controls in clinical trials with longitudinal outcomes using the modified power prior.
    Qi H; Rizopoulos D; Lesaffre E; van Rosmalen J
    Pharm Stat; 2022 Sep; 21(5):818-834. PubMed ID: 35128780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elastic priors to dynamically borrow information from historical data in clinical trials.
    Jiang L; Nie L; Yuan Y
    Biometrics; 2023 Mar; 79(1):49-60. PubMed ID: 34437714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian borrowing from historical control data in a vaccine efficacy trial.
    Peng L; Jin J; Chambonneau L; Zhao X; Zhang J
    Pharm Stat; 2023; 22(5):815-835. PubMed ID: 37226586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring exchangeability in data-based priors for a Bayesian analysis of clinical trials.
    Lin J; Gamalo-Siebers M; Tiwari R
    Pharm Stat; 2022 Mar; 21(2):327-344. PubMed ID: 34585501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matching design for augmenting the control arm of a randomized controlled trial using real-world data.
    Liu Y; Lu B; Foster R; Zhang Y; Zhong ZJ; Chen MH; Sun P
    J Biopharm Stat; 2022 Jan; 32(1):124-140. PubMed ID: 35098880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.